Prevention of lung disease is the major therapeutic imperative for patients with this genetic disorder. Definitive treatment involves replacement or augmentation of antielastase with human plasma-derived protease inhibitor in patients with early or mild chronic obstructive pulmonary disease. Measures to minimize the risk of serious hepatic involvement remain to be devised.